(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase ...
INDIANAPOLIS (dpa-AFX) - Eli Lilly And Co. (LLY) revealed earnings for its first quarter that increased from the same period last year and beat the Street estimates. The company's earnings totaled ...
In den letzten 12 Monaten haben Analysten für die Eli Lilly & insgesamt 9 Mal die Bewertung "Gut", 2 Mal die Bewertung "Neutral" und 0 Mal die Bewertung "Schlecht" vergeben. Langfristig erhält ...
Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
(RTTNews) - Eli Lilly And Co. (LLY) revealed earnings for its first quarter that increased from the same period last year and ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE: LLY )'s weight-loss drug Zepbound drove the ...